Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Website
Linkedin

ORCID
https://orcid.org/0000-0002-2342-8531

Yama F Mujadidi

BCA Computer Application , MSc in Information Technology and Software Engineering

Programming and Data Management Director

Automation and Semantic Interoperability in Clinical Trials

Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.

Recent publications

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), J Infect, 92

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Janani L. et al, (2025), J Infect, 91

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Li G. et al, (2025), Vaccine, 62

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model.

Ashton PM. et al, (2025), Microbiome, 13

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.

Chanda C. et al, (2025), Lancet Microbe, 6

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.

Feng S. et al, (2025), J Infect, 90

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.

Conlin K. et al, (2025), Vaccine, 45

Five-Year Vaccine Protection Following a Single Dose of Vi-Tetanus Toxoid Conjugate Vaccine in Bangladeshi Children: A Cluster Randomised Trial

Qadri F. et al, (2024)

5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.

Qadri F. et al, (2024), Lancet, 404, 1419 - 1429

Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.

Dyson ZA. et al, (2024), Lancet Microbe, 5

Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.

Khaki JJ. et al, (2024), Sci Rep, 14

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe, 5, 655 - 668

Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.

Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025

Evaluating the relationship between ciprofloxacin prescription and non-susceptibility in Salmonella Typhi in Blantyre, Malawi: an observational study.

Ashton PM. et al, (2024), Lancet Microbe, 5, e226 - e234

Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.

Hill M. et al, (2023), BMJ Open, 13

SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood.

Lugar M. et al, (2023), JAMA, 330, 1151 - 1160

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

Direct inference and control of genetic population structure from RNA sequencing data.

Fachrul M. et al, (2023), Commun Biol, 6

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.

Kelly S. et al, (2023), Trials, 24

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), J Infect, 87, 18 - 26

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect, 86, 574 - 583

Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.

Khanam F. et al, (2023), Vaccine, 41, 3137 - 3140

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), J Infect, 86, 540 - 541

The rapid emergence of Salmonella Typhi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi

Ashton PM. et al, (2023)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.

Bendor-Samuel OM. et al, (2023), Arch Dis Child, 108, 26 - 30

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060

More publications